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ABSTRACT                                                                                                                                                                                                                 
Background: Burkina Faso is one of the countries in West Africa most affected by the HIV/AIDS pandemic, despite the 
implementation of a mother-to-child HIV transmission prevention program as a strategy to reduce the risk of vertical 
transmission of the disease. 
Objective: To assess the current risk of mother-to-child transmission of HIV in Burkina Faso. 
Materials and methods: A prospective study was conducted between December 2014 and July 2016, in the 13 health regions 
of Burkina Faso. Women who were screened HIV-positive during a prenatal consultation were followed until delivery. 
Their babies received dry blood spot (DBS) at birth, at week 6 and at 1year, to screen for HIV. 
Results: Overall, 186 pregnant women were included in the study, with a mean age of 29.17±6.13 years. Of their children, 
430 DBS actually received a PCR test, giving a 91.1% PCR implementation rate. After analyses, 6 (1.3%) babies were 
identified as carriers of HIV1. The newborn’s serological status was associated with delivery pattern (p=0.000), the 
administration of antiretroviral drugs to the mother after delivery (p=0.0064), the administration of Nevirapine to the 
newborn at birth (p=0.022), the use of contraceptive methods after delivery (p=0.028) and the presence of breast 
affections/infections since delivery (p=0.013).  
Conclusion: The results of our study are encouraging and demonstrate the effectiveness of interventions in the mother-to-
child prevention program (PMTCT) for HIV-positive pregnant women can be improved through early initiation of triple 
therapy in early pregnancy and improved adherence to antiretroviral (ARV) therapy. 
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RÉSUME                                                                                                                                                                                                               
Contexte : Le Burkina Faso fait partie des pays les plus touchés par la pandémie du VIH/sida, malgré la mise en place d’un 
programme de transmission mère/enfant du VIH comme stratégie de prévention de la transmission verticale. 
Objectif : l’objectif était d’évaluer le risque résiduel actuel de transmission du VIH de la mère à l’enfant au Burkina Faso. 
Matériel et Méthode : Il s’agit d’une enquête prospective simple à visée descriptive et analytique réalisée entre décembre 
2014 et juillet 2016, dans les 13 régions sanitaires du Burkina Faso. Les femmes reçues en consultation prénatale dépistées 
séropositives ayant donné leur consentement éclairé étaient suivies jusqu’à l’accouchement. Leurs enfants ont bénéficiés 






Résultats : Au total 186 femmes enceintes ont été enregistrées dans l’ensemble des sites de l’étude dont l’âge moyen était de  
29,17 ans avec un écart type de ± 6,13. A partir des enfants nés de ces femmes, 430  DBS ont effectivement bénéficié d’un 
examen PCR soit 91,1% de taux de réalisation de PCR. A la suite des analyses six (06) enfants étaient porteurs de VIH1 soit 
1,3% de la population d’enfants testés. Le statut sérologique du bébé était associé au  mode de délivrance (p = 0,000),  à 
l’administration de médicaments antirétroviraux à la mère après l’accouchement (p = 0,0064), à l’administration de la 
névirapine au nouveau-né à la naissance (p = 0,022), à l’utilisation de méthodes contraceptives après l’accouchement (p = 
0,028) et à la présence des affections/infections au sein depuis l’accouchement (p = 0,013). 
Conclusion: Les résultats de notre étude sont encourageants et démontrent que l'efficacité des interventions dans le 
programme de prévention de la transmission mère l'enfant (PTME) pour les femmes enceintes séropositives peut être 
améliorée par l'initiation précoce de la trithérapie au début de la grossesse et l'amélioration de l'observance des 
antirétroviraux (ARV). 
Mots-clés: Burkina Faso, VIH / SIDA, transmission mère-enfant, médicaments antirétroviraux, femmes enceintes 
INTRODUCTION 
Burkina Faso is one of the countries in West Africa 
most affected by HIV/AIDS. The first estimate of 
HIV seroprevalence in the general population in 
1997 was7.1% (1,2). In the pregnant population, 
mean HIV seroprevalence in seroprevalence sites 
(sentinel sites in the health district where mother-
to-child transmission of HIV is actively monitored) 
was 6.5% in 2002 (3, 4). In 2006, this figure was 
estimated at 2.5% and at 2% in 2010, according to a 
joint United Nations Program on 
HIV/AIDS/World Health Organization 
(UNAIDS/WHO). This reduction in seroprevalence 
required a series of measures to control the disease, 
initially based on education sensitization and 
information. Since the mid-1980s, several 
researchers have studied mother-to-child 
transmission of HIV. These studies were needed to 
provide estimates on mother-to-child HIV 
transmission, demographic forecasts, to compare 
rates of transmission in different epidemiological 
contexts and to understand the determinants of 
mother-to-child transmission to identify factors 
amenable to interventions and counseling services 
(individual counseling and care for mothers and 
children) (2). 
As of 2000, a strategic plan to combat HIV/AIDS 
and sexually transmitted infections (STIs) was 
adopted by the Burkina Faso government. The 
strategic plan identified areas for action, including 
reducing the spread of HIV as a result of a national 
program to prevent mother-to-child transmission of 
HIV (PMTCT/HIV). Since 2002, Burkina Faso has 
implemented a program to prevent mother-to-child 
transmission of HIV, aimed at increasing the 
number of women giving birth to children free from 
HIV/AIDS. The first PMTCT/HIV program was 
implemented between 2002 and 2005 and was used 
as a prevention strategy against vertical 
transmission. The program included the provision 
of higher-quality and lower-risk obstetric care, the 
administration of Nevirapine to the mother 
peripartum (2 mg/kg bodyweight) and the choice 
between exclusive breast milk substitutes or 
exclusive breastfeeding for up to 4 months,  
 
 
followed by early weaning (5,6).The second 
program, implemented between 2006 and2010,used 
the same strategies, except the antiretroviral (ARV) 
regimen, which included the administration of 
three ARVs: one from the 28thweek of pregnancy, 
three peripartum and two postpartum (5,6,7). This 
program reduced the risk of vertical transmission to 
less than 5%, when properly applied (WHO, 2004). 
The third PMTCT/HIV program, for the period 
between 2011 and2015, proposed prophylaxis or 
ARV treatment protocols form others, to reduce 
mother-to-child transmission of HIV. Secure 
feeding and ARV prophylaxis were also offered to 
the newborn infant. This program uses two 
sequential protocols in options A and B, (initially 
3years for option A and 2years for option B). Option 
A was introduced in 2010 and includes a single 
dose of ARVs for women (if their CD4 count is over 
350) from the 14th week of pregnancy, as well as 
ARV during labor and delivery, and for 1week after 
birth. Option B, introduced by WHO at the same 
time as option A, consists of antiretroviral 
combination therapy from the 14th week of 
pregnancy until 1week after the end of 
breastfeeding, to 1year (8).A requirement for 
moving from one option to the next is to bring 
together the human, material and financial means 
necessary to make this change. In the end, option A 
lasted for 4years, from 2011 to 2014.Other 
innovations include early prophylactic care that 
corresponds to the 14thweek of pregnancy and the 
concept of safe breastfeeding. The aim of this 
program, which is based on WHO option B+ (tri-
therapy as soon as the mother is notified of her 
HIV-positive status and treatment of the child 
(NVP/AZT) for 4 to 6 weeks), is to eliminate 
mother-to-child transmission of HIV in Burkina 
Faso.  
A previous residual transmission cross-sectional 
study, conducted in 2008, highlighted a very high 
prevalence of 3.3% (9). It is in this context the 
present study was initiated; with the aim of 
assessing the impact of the intervention on residual 
vertical transmission of HIV and to identify its 






MATERIALS AND METHODS                                                        
Study design and sampling                                                 
This prospective study was conducted between 
December 2014 and July 2016, in the Central and 
Hauts-Bassins regions of Burkina Faso. 
Convenience sampling at two levels (district and 
region) was performed and took into account all 13 
health regions in the country. Health districts with 
the highest HIV prevalence among pregnant 
women were selected. In addition, PMTCT sites 
with the best immunization coverage (at 6 or 10 
weeks) were also selected. Overall, 10 PMTCT sites 
in each of the three major districts of the Central 
and Hauts-Bassins regions and one or two PMTCT 
sites in other areas of the country were selected. 
Data collection involved 34 PMTCT sites in 14 
health districts. 
Target population                                                                                                                                                                             
The target population was pregnant women 
identified as HIV-positive during the prenatal 
consultation screening and HIV-positive 
breastfeeding women and their babies, who gave 
their informed consent to participate in the study.  
Sample size                                                                                                                                                                                             
The sample size was estimated at 155 pregnant 
women and 132 children. The number of HIV-
positive women needed was estimated as follows: 
The total number of HIV-positive women expected 
in the district on the number of PMTCT sites in the 
district should be divided by four (the number of 
quarters in a year).Total number of HIV-positive 
women expected in the district = number of HIV-
positive women expected per PMTCT site during 
the recruitment phase, which is 3 months. The 
number of children needed was estimated on the 
basis of the expected number of children born to 
HIV-positive mothers in PMTCT sites retained for 3 
months. 
Data collection                                                                                                                                                                                          
Enrollment of pregnant women was done during 
the prenatal consultation, regardless of the stage of 
pregnancy. A questionnaire was developed to 
gather data on socio-demographic characteristics 
and to identify risk factors for mother-to-child 
transmission. This included monitoring of women 
in the study from pregnancy to postpartum, 
compliance with refocused schedules for prenatal 
consultations, compliance with the applicable 
PMTCT protocol (by infected pregnant women, 
infected parturients, nursing mothers, exposed 
children), type of delivery (surgery or vaginal 
delivery, at home or at the health center) and 
invasive practices during childbirth, newborn and 
infant feeding patterns and the evolutionary phase 
of HIV infection.  
Dry blood spot (DBS) samples were obtained from 
babies and used for PCR at birth, at 6 weeks of life 
when screened negative at birth, and finally at 
1year, when the first two tests were negative by 
PCR. A child was declared negative after three 
negative PCR tests.The sampling was performed on 
the newborn’s heel on the lateral or medial side of 
the foot. Cards (DBS) were dried at laboratory 
temperature, out of direct sunlight on a rack, for at 
least 3 hours or overnight. They were then stored in 
plastic bags with a desiccant at -20º C. 
Laboratory analysis                                                                                                                             
In the laboratory, DNA extraction was performed 
using the extraction kit on the DBS. After extraction, 
DNA amplification was performed using the real-
time PCR kit for the qualitative or quantitative 
detection of HIV-1 cellular DNA. The evolution of 
the amplification is represented by a sigmoid-like 
curve, which can be divided into two phases. At the 
beginning of the exponential amplification phase, 
the time when the signal leaves the background
noise corresponds to a number of cycles called Ct 
(threshold cycle); during this exponential 
amplification phase, the quantity of PCR products 
obtained at each moment directly depends on the 
initial copy number. The second phase is a plateau 
phase, which corresponds to a slowing-down of the 
amplification of the reaction because of depletion of 
reagents. 
Reading and interpretation of results                                                                                                                              
The PLC is equipped with a system enabling 
analysis of the results. It determines the threshold 
value of the reaction as well as the Ct value of each 
standard of the range i.e. the intersection between 
the threshold value and the amplification curve. 
The Ct values corresponding to the samples of 
unknown values are reported on the right of the 
abscissas, and then the number of copies of 
DNA/PCR is extrapolated. Results are qualitative. 
Ethical Considerations                                                                                                                
The study was approved by Burkina Faso Ethics 
Committee for Health Research through
proceedings N° 2014-8-101.  
RESULTS                                                                                                                                                                                           
Socio-demographic characteristics                                                                                                                
A total of 186 pregnant women were enrolled on 
the study, across all the study sites. Of the 
participants, 70.4% were from the central region, 
9.7% from Hauts-Bassins and 7.5% from the 
northern regions. Age ranged from 17–43 years, 
with a mean age of29.17±6.13 years. Overall, 47.8% 
of women had not attended school, 21.5% had 
primary and 25.2% had secondary school level 
education. Less than 2% of participants had a 
higher education level. Mother's medical history                                                            
More participants who shared their positive 
serology results with their partner gave birth to 
uninfected newborns, compared with those who 





Information on delivery                                                                                                                                                                      
In this study, 95.5% of women had a full-term 
pregnancy and 96% delivered in a health center 
(63.2% in the health center where they had their 
prenatal consultations and 32.8% in other health 
centers). In total, 90.9% of women had vaginal
deliveries however, 4.5% of the study population 
gave birth prematurely and 4.01% gave birth at 
home.  
  
















(All women irrespective of 
the serology of the baby) 
Age group of surveyed 
individuals 
Under 25 years 20.4 33.3 20.9 0.678 0.712 (ns) 
25-34 years 53.5 50.0 53.4 
Above 35 years 26.1 16.7 25.8 
Literacy Level Illiterate  48.8 33.3 48.3 2.078 0.721 (ns) 
Primary school 20.3 16.7 20.2 
Secondary school 25.0 50.0 25.8 
Higher education 1.7 0.0 1.7 
Other  4.1 0.0 3.9 
Marital Status In couple without co-
spouse  
73.3 50.0 72.5 8.087 0.044 (**) 
In couple with co-spouse 17.4 16.7 17.4 
Single /divorced 5.2 33.3 6.2 
Other  4.1 0.0 3.9 
Residence Area Urban 73.8 83.3 74.2 0.273 0.512  (ns) 
Rural 26.2 16.7 25.8 
Occupation  Public Sector employee  4.7 16.7 5.1 11.529 0.073 (ns) 
Private Sector employee 4.1 0.0 3.9 
Merchant 14.5 0.0 14.0 
Farmer  1.2 0.0 1.1 
Pupil /student 1.2 16.7 1.7 
Housewife  67.4 66.7 67.4 
Other  7.0 0.0 6.7 
ns = not significant, ** = significant at 5% ; Marital status (couple, or divorced/single) was significantly associated with the newborn's 
positive serological status (p=0.044). 










Negative Positive Aggregate 
Number of prenatal consultations 
corresponding to the start of ARV 
treatment.  
CPN 1 62.4 40.0 61.4 3.287 0.349 (ns) 
CPN 2 25.7 40.0 26.3 
CPN 3 7.3  7.0 
CPN 4 4.6 20.0 5.3 
How many weeks do you estimate 
the length of this ARV treatment 
before childbirth 
Less than 4 weeks 7.8  7.5 0.419 0.674 (ns) 
At least 4 weeks before delivery 92.2 100.0 92.5 
Sharing results with your partner Yes 55.7 0 53.7 7.211 0.009 (**) 
No 44.3 100.0 46.3 
ns = not significant,** = significant at 5%  
 
There was a significant association between the 
newborn’s serological status and the pattern of 
delivery (p=0.000); the risk is high when it comes to 
a guided delivery. Managing the woman without 
the partner's support increased the risk of HIV 
transmission for the newborn (p=0.009). 
Antiretroviral drug administration to the mother 
after delivery (p=0.044) and administration of 
Nevirapine to newborns at birth was associated 
with a lower rate of seropositivity in newborns 
receiving Nevirapine at birth, compared with those 
who did not receive this treatment (p=0.022). 
PCR results                                                                                             
Three (1.96%; 95% confidence interval [CI] 0–4.6) 
babies were HIV-positive at birth. Two (1.34%; 
95%CI 0–3.4) babies were HIV-positive at 6weeks of 
age (both of these babies were born negative). One 
baby (0.78%; 95%CI 0–2.3) was HIV-positiveat 12 
months of age.This baby was negative at birth but 
could not be tested at 6 weeks of agebecause his 





TABLE 3: BIVARIATE DATA ANALYSIS ON DELIVERY 
Variable Terms  
Newborn’s Serology Chi-Square 
value 
Meaning  
Negative Positive Aggregate  
Provide information on 
delivery pattern 
Natural 8.6 0.0 8.3 20.527 0.000  
(***) 
Artificial 10.5 0.0 10.1 
Guided  79.0 66.7 78.6 
Don’t know 1.9 33.3 3.0 
Were there any 
complications during the 
delivery? 
Yes  12.9 0.0 12.4 0.883 0.445 
 (ns) 
No 87.1 100.0 87.6 
Mother’s treatment during 
labor 
Nvp 13.3 20.0 13.5 1.709 0.635 
 (ns) AZT/3TC 10.1 0.0 9.8 
None  20.9 40.0 21.5 
Other  55.7 40.0 55.2 
Did the mother receive 
antiretroviral drugs after 
delivery 
Yes  93.6 66.7 92.6 10.106 0.044  
 (**) No 6.4 33.3 7.4 
Did the newborn receive 
nevirapine at birth 
Yes  96.8 66.7 95.7 12.686 0.022  
(**) No 3.2 33.3 4.3 
Did the newborn received 
other ARV than Nevirapine 
since his birth 
Yes  9.7  9.3 0.640 0.551  
(ns) No 90.3 100.0 90.7 
Did the newborn already 
make HIV test (PCR) at birth 
 





No 9.3  0 8.9 
ns = not significant,** = significant at 5%  
FIGURE 1: MOTHER-TO-CHILD TRANSMISSION RATE 
 





Meaning Negative Positive Aggregate  
Newborn feeding pattern 
since his birth 




Mixed breastfeeding 8.6 55.5 9.5 
Artificial feeding 0.7  0.6 
Has he drunk water, fruit 
juice, traditional products 
since his birth? 




No 57.4 50.0 57.1 
Don’t know 6.1  5.8 
Has the newborn been sick 
since his birth? 
Yes 44.1 60.0 44.7 
0.492 
0.399 
 (ns) No 55.9 40.0 55.3 
If AME is practiced, please 
specify the length 




0-5 months 13.7  13.3 
0-6 months 69.5 66.7 69.4 
After AME, how long has 
the woman screened 
seropositive proceeded 
with breastfeeding? 




6 months 20.2 66.7 21.8 


















Transmission at 6 
week of life
Cumulative 


















TABLE 4B: BREASTFEEDING AND POSTPARTUM MONITORING 
Variable Terms  
Newborn’s Serology Chi-Square 
value 
Meaning 
Negative Positive Aggregate  
Did the mother have postnatal consultation 
Yes 85.2 80.0 85.0 
0.103 0.561 (ns) 
No 14.8 20.0 15.0 
ARV treatment used by the mother screened 
positive  
Yes 93.0 100.0 93.1 
0.227 0.806 (ns) 
No 7.0 0.0 6.9 
After delivery, does she use a family 
planning method 
Yes 52.1 0.0 50.3 
5.247 0.028 (**) 
No 47.9 100.0 49.7 
Is the newborn under prophylaxis with 
Cotrimoxazole 
Yes 86.2 75.0 85.9 
0.405 0.459 (ns) 
No 13.8 25.0 14.1 
Have you be subject to  breast 
affections/infections since delivery  
Yes 
3.7 50.0 5.1 
17.268 0.013 (**) 
No 96.3 50.0 94.9 
Ns = not significant, ** = significant at 5% 
Table 4b shows that mothers who used contraceptive 
methods after delivery had fewer seropositive babies 
than those who did not (p=0.028). Mothers who 
reported having post-partum breast 
affections/infections had more positive babies than 
those who did not(p=0.013). 
DISCUSSION                                                                                                                                                                                       
The main objective of our study was to assess the 
current residual risk of mother-to-child transmission 
of HIV in Burkina Faso. Out of a sample of 186 HIV-
positive women, six (1.3%) of their children were 
positive forHIV-1.This national study involved 14 
districts out of 13 health regions in Burkina Faso. 
However, it should be noted that the contribution of 
the Bobo Dioulasso districts to the study was quite 
small. Out of the three health districts, Do, Dafra and 
Karangasso-Vigué, which were expected to contribute 
a minimum of 60 samples, only Karangasso-Vigué 
district provided 16 samples, reducing the sample size 
of the study. More participants from the Hauts-
Bassins region would have made it possible to obtain 
a larger sample enabling us to analyze data for both 
regions (Central and Hauts-Bassins) separately. 
However, all these data have helped to better 
understand the rate of residual HIV transmission in 
Burkina Faso. 
In the present study, six exposed children were born 
HIV1-positive, three of them at birth and two were 
positive at 6 weeks. At 1 year, there was an additional 
positive child. These results are encouraging 
compared with previous sero-surveillance data in 
Burkina Faso, where the estimated percentage of 
children infected with HIV through vertical 
transmission from their HIV-positive mothers who 
have given birth in the last 12 months in2013, 2014, 
2015 was 5.72%, 5.30% and 4.95%,respectively (10). In 
other countries such as China, the vertical 
transmission rate was reported as 6.7% in 2013 (11) 
and in Ukraine in 2010 it was reported as 4.1% (12), 
despite the implementation of PMTCT programs. In 
addition, similar vertical transmission rates have been 
reported in other countries, particularly South Africa, 
where surveys conducted in 2010 and 2011 revealed 
vertical transmission rates of 3.5% and 2.7%, 
respectively (13).  
MTCT is responsible for the majority of HIV infections 
in children, with 10,000 new cases of infected 
newborns each year in Burkina Faso (UNDP, 2001). 
With a lack of specific action to reduce the risk of 
transmission, estimated rates of mother-to-child or 
vertical transmission range between 14% and 25% in 
Europe and United States and between 13% and 42% 
in developing countries (14). In 1997, the rate of MTCT 
was very high in developing countries, up to 25% and 
35%, while in France and in the United States, the rate 
was less than 5% (15). The two main reasons for this 
are breastfeeding practices and access to drugs to 
reduce mother-to-child transmission. Furthermore, it 
is recognized that under a PMTCT intervention, the 
MTCT rate may fall below 5% (13). In developed 
countries, MTCT rates have declined recently, 
sometimes to less than 2%, because of the 
effectiveness of interventions to prevent this 
transmission (16). By 2015, some countries such as 
Cuba had already successfully eliminated MTCT 
(UNAIDS/WHO, 2015). In Burkina Faso, risk factors 
for mother-to-child transmission of HIV are related to 
pregnancy (nutritional status, sexually transmitted 
infections, anemia), labor/delivery (traumatic 
obstetric procedures) and extended breastfeeding 
until the age of 2years (6; 17).  
It is important to note the difficulty of comparing 
different studies on the rate of mother-to-child 
transmission of HIV, because of the multiplicity of 
methodological approaches. In our study, all mothers 
of HIV-positive children started with triple therapy, at 
least 4 weeks before delivery. However, during and 
after childbirth, nearly 21.7% and 8.4% of women, 
respectively, received no ARV treatment. Among 
those who received it during labor, about 40% were 
on triple therapy, 13.3% treated with Nevirapine and 
about 10.8% with AZT/3TC.After delivery, only 50% 
of women benefited from triple therapy and 9% from 





B+ option was not respected, i.e. starting triple 
therapy, which will be continued for the remainder of 
their life time as soon as the diagnosis is made in the 
mother and child and administration of NVP or AZT 
(2 mg/kg/day) single-dose for 4 to 6 weeks, 
irrespective of the newborn feeding method.  
One of the issues this study assessed as part of the 
mother's history was the sharing of her serological 
status with her spouse. Almost half of women 
surveyed (48.9%) already knew their serological status 
before pregnancy. Of these, 89% knew they were HIV-
positive. However, 47.9% of women in the study were 
unable to share their HIV status with their partners 
and none of the HIV-positive women had shared their 
HIV status with their partners. The reasons given 
include fear of being rejected by their partner, 
stigmatization and conflicts in the home. This shows 
the importance of the community in supporting HIV-
positive women and the involvement of men in the 
TME program. This family dimension of PMTCT is a 
reality. Indeed, previous studies and experiences of 
the actors showed that women have difficulty in 
revealing their HIV serological status to their partners, 
especially during pregnancy, even if access to 
treatment that now enables the diagnosis makes 
sharing less difficult than in early 2000 (18). 
In this study, two variables were significantly 
associated with newborn positive serology: use of 
contraceptive methods after childbirth and breast 
affections/infections since childbirth. There were also 
higher rates of the following variables in mothers with 
HIV-positive children: mixed breastfeeding, ingestion 
of water, fruit juice and traditional products, an 
episode of  disease in the newborn(skin infections 
were reported in three children),exclusive 
breastfeeding practice between 0 and 3 months, 
breastfeeding for 6 months and non-use of family 
planning (FP) by the mother. 
According to data from the early 1990s, the estimated 
risk of breast milk transmission in HIV-positive 
women was about 15%, if breastfeeding was 
continued for 2years or more (19. The risk of 
transmission through breastfeeding in women with 
recent (postpartum) infection was nearly twice as high 
(20). 
In our study, the two babies who were positive at 6 
weeks were negative at birth. In the first case, 
exclusive breastfeeding was performed for 3months 
and in the second case, exclusive breastfeeding was 
continued for 6 months. Factors that may increase the 
risk of MTCT during breastfeeding, according to 
WHO, include oral thrush and/or oral ulcers of the 
newborn and cracks, crevices, mastitis and mammary 
abscesses in the mother. None of these factors were 
found in the two positive infants. There was no 
statistically significant correlation between 
breastfeeding and HIV serology in our study. This 
could be because of the limited number of babies 
found seropositive during the breastfeeding period. 
In this study, triple therapy onset was delayed (after 
the third month of pregnancy) and the irregularity or 
even absence of ARV treatment during delivery and 
postpartum was observed in more than half of HIV-
positive mothers. The first late prenatal consultation, 
ARV unavailability and insufficient sensitization of 
women on the need to take these drugs are elements 
that we found in this study. If the PMTCT protocol is 
followed appropriately, it can significantly reduce the 
risk of mother-to-child transmission of HIV-1 or even 
reduce the HIV-1 vertical transmission rate to 0.0% 
(21). Also, our study found that mother-to-child 
transmission of HIV was higher in women who had 
vaginal delivery;20% compared with 14% for women 
who gave birth by caesarian. 
CONCLUSION                                                                                                                                                                                  
The residual MTCT rate was1.96% at birth, 1.34% at 6 
weeks and 0.78% at 12 months. The cumulative rate at 
6 weeks was2.94% and from birth to 12 months 
was3.37%.These results provide hope in the fight 
against HIV in Burkina Faso. The analysis of factors 
impacting MTCT has demonstrated the effectiveness 
of PMTCT interventions for HIV-positive pregnant 
women. These interventions could have been 
improved through the early commencement of triple 
therapy in early pregnancy and improved adherence 
to ARV therapy. No HIV-positive women in the study 
who gave birth to an HIV-positive baby shared her 
HIV status with her partner. Women’s partners 
should be involved in the implementation of the 
program to help these women and ensure their proper 
care. Early and permanent community involvement 
must be effective throughout the continuum of the 
provision of integrated care (maternal neonatal and 
child health/PMTCT). The community plays an 
important role in HIV management within couples 
and therefore contributes to the success of the PMTCT 
program. 
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